You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Details for Patent: 4,959,472


✉ Email this page to a colleague

« Back to Dashboard


Title: Process for preparing substantially pure diastereoisomers of tetrahydrofolic derivatives
Abstract:The present invention related to the preparation of substantially pure diastereoisomers of derivatives of tetrahydrofolate and the use of such diastereoisomers. More particularly the present invention provides a process for the preparation of a desired substantially pure (6R or 6S) diastereoisomer of a derivative of tetrahydrofolic acid or salt or ester. The process comprises the steps of: attaching a chiral auxiliary group at either N-5 or N-10 of a mixture of 6R and 6S diastereoisomers of tetrahydrofolic acid, separating the new diastereoisomers, recovering the desired new diastereoisomer (6R or 6S) corresponding to the desired (6R or 6S) diastereoisomer, and converting the substantially pure new diastereoisomer recovered into the corresponding diastereoisomer.
Inventor(s): Wood; Hamish C. S. (Glasgow, GB6), Suckling; Colin J. (Glasgow, GB6), Rees; Lilias G. (Glasgow, GB6)
Assignee: University of Strathclyde (Glasgow, GB6)
Filing Date:Sep 01, 1989
Application Number:07/403,917
Claims:1. A process for the preparation of a desired substantially pure (6R or 6S) disastereoisomer of a derivative of tetrahydrofolic acid selected from leucovorin (5- formyltetrahydrofolic acid) or a salt or ester thereof, and 5- methyl-or 5,10-methylene or 5,10 methanol-tetrahydrofolic acid or a salt or ester thereof which process compresses the steps of:

(a) attaching a chiral auxiliary group at either N-5 or N-10 of a mixture of 6R and 6S disastereoisomers tetrahydrofolic acid or of a substituted tetrahydrofolic acid or said or ester thereof, so as to form a pair of new diastereoismers, said chiral auxiliary group is one alcohol selected from the group consisting of (-) menthol, (-) boneol, (-) isoborneol;

(b) separating the pair of new diastereoisomers and recovering the new diastereoisomer (6R or 6S) diastereoisomer; and corresponding to said desired (6R or 6S) diastereoisomer; and

(c) converting the substantially pure new diastereoisomer so isolated into the corresponding desired substantially pure (6R or 6R) diastereoisomer of a derivative of tetrahydrofolic acid or salt or ester thereof.

2. A process according to claim 1 which includes the step or removal of the chiral auxiliary group.

3. A process according to claim 6 in which process is obtained a substantially pure (6S) diastereoisomer of 5,10-methenyltetrahydrofolic acid or a salt or ester thereof, which process includes the step of further converting the substantially pure (6S) diastereoisomer of 5,10-methenyltetrahydrofolate into a substantially pure (6S) diastereoisomer of 5-formyl-or 5-methyl tetrahydrofolic acid or salt or ester thereof.

4. A process according to claim 1 wherein said new diastereoisomer is isolated by means of solvent extraction or fractional crystallisation or chromatography.

5. A process according to claim 8 wherein said solvent extraction or fractional crystallisation is effected with a polar solvent.

6. A process according to claim 9 wherein said solvent extraction or fractional crystallisation is repeated until the recovered new diastereoisomer has a purity of greater than 90%.

7. A process according to claim 1 wherein the derivative of tetrahydrofolic acid or salt or ester thereof obtained is a substantially pure (6R) diastereoisomer of leucovorin (5-formyltetrahydrofolic acid) or said or ester thereof.

8. A process for the preparation of a desired substantially pure (6R or 6S) diastereoisomer of a derivative of tetrahydrofolic acid selected from leucovorin (5-formyltetrahydrofolic acid) or a salt or ester thereof, and 5-methyl-or 5,10-methylene or 5,10 methanol-tetrahydrofolic acid or a salt or ester thereof which process comprises the steps of:

(a) attaching a chiral auxiliary group selected from (-) menthol, (-) borneol, or (-) isoborneol, at either N-5 or N-10 of a mixture of 6R and 6S disastereoisomers of tetrahydrofolic acid or of a substituted tetrahydrofolic acid or salt or ester thereof by reaction with (-) menthyl chloroformate, (-) borneol chloroformate, or (-) isoborneol chloroformate respectively, so as to form a pair of new diastereoisomers;

(b) separating the pair of new diastereoisomers and recovering the new diastereoisomer (6R or 6S) diastereoisomer; and corresponding to said desired (6R or 6S) diastereoisomer; and

(c) converting the substantially pure new diasteroisomer so isolated into the corresponding desired substantially pure (6R or 6S) diastereoisomer of a derivative of tetrahydrofolic acid or salt or ester thereof.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.